Hepion Pharmaceuticals Inc (HEPA) concluded trading on Wednesday at a closing price of $0.14, with 35.16 million shares of worth about $4.92 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -83.93% during that period and on January 22, 2025 the price saw a loss of about -58.05%. Currently the company’s common shares owned by public are about 6.96M shares, out of which, 6.95M shares are available for trading.
Stock saw a price change of -71.58% in past 5 days and over the past one month there was a price change of -75.89%. Year-to-date (YTD), HEPA shares are showing a performance of -71.28% which decreased to -93.66% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.28 but also hit the highest price of $3.49 during that period. The average intraday trading volume for Hepion Pharmaceuticals Inc shares is 81.65K. The stock is currently trading -71.81% below its 20-day simple moving average (SMA20), while that difference is down -76.32% for SMA50 and it goes to -84.99% lower than SMA200.
Hepion Pharmaceuticals Inc (NASDAQ: HEPA) currently have 6.96M outstanding shares and institutions hold larger chunk of about 7.84% of that.
The stock has a current market capitalization of $0.94M and its 3Y-monthly beta is at 1.67. It has posted earnings per share of -$4.39 in the same period. It has Quick Ratio of 1.30. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for HEPA, volatility over the week remained 25.24% while standing at 15.14% over the month.
Analysts are in expectations that Hepion Pharmaceuticals Inc (HEPA) stock would likely to be making an EPS of 0 in the current quarter, while forecast for next quarter EPS is 0 and it is 0 for next year. For the current quarter EPS, analysts have given the company a lowest target 0 which is 0 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -3.48 in the same quarter a year ago.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by ROTH Capital on July 20, 2020 offering a Buy rating for the stock and assigned a target price of $14 to it.
